Notably, capmatinib has already shown significant antitumor activity in patients with advanced NSCLC harboring c-MET exon 14 skipping mutations, particularly in treatment-naïve individuals (Wolf et al., 2020). This evidence concerns the gene MET and non-small cell lung carcinoma.